DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of VONJO® (pacritinib)
– Uncapped deal structure complements current VONJO royalty entitlement – – Now projecting Total Income CAGR at high end of our 7-9% guidance through 2025 and flat to slightly growing Total…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Net Sales of Orserdu™ (elacestrant) and Reiterates Long-Term Cash Receipts Outlook
– Patent-protected exclusivity and uncapped deal structure offers attractive return profile – – Acquisition generates substantial near-term cash flows and long-term portfolio growth – –…
DRI Healthcare Trust Announces US$54.8 Million Debt Repayment from CTI BioPharma Corp.
– Provides additional deployment capacity in pursuing attractive deals in high-quality pipeline – TORONTO, June 26, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the “Trust”),…
DRI Healthcare Trust Announces Voting Results of AGM
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) is pleased to announce results of voting at its annual general meeting (“AGM”) of unitholders held on May 12, 2023. All of…
DRI Healthcare Trust Reports First Quarter 2023 Results
– Robust royalty transaction activity showcases ability to execute on attractive deals – – Continued strong performance of existing assets and financial results – TORONTO, May 11, 2023…
DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that the Trust intends to participate in the following investor conferences in spring 2023: RBC Global…
DRI Healthcare Trust to Host First Quarter Earnings Call and Webcast on May 12, 2023
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it will hold a conference call to discuss its first quarter financial results on Friday, May 12, 2023,…
DRI Healthcare Trust Announces Sale of its TZIELD™ Royalty Interest to Sanofi for US$210 Million and Announces a US$20 Million Special Cash Distribution to Unitholders
– Transaction will allow DHT to redeploy capital into new deals generating compounding returns for unitholders – TORONTO, April 27, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U)…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of TZIELD™ (teplizumab-mzwv) and Updates Long-Term Cash Receipts Outlook
– Transaction adds a ground-breaking type 1 diabetes therapy to DRI’s expanding portfolio – – Excluding any new transactions, DRI now expects 2030 cash receipts to be at least as high as…
DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2022 Results
– 2022 deployment of US$281 million continues to validate growth strategy – – Continued strong performance of existing assets and financial results – TORONTO, March 1, 2023 /CNW/ – DRI…